Hematologic Neoplasms × Cyclophosphamide × Lymphoid × Clear all
NCT06904066 2026-03-18

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
86 enrolled
NCT02861417 2026-02-17

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
204 enrolled
NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Case Comprehensive Cancer Center

Phase 1 Suspended
12 enrolled
NCT03670966 2025-10-16

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
30 enrolled
NCT03399773 2025-08-26

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Fred Hutchinson Cancer Center

Phase 2 Active not recruiting
31 enrolled
NCT05735717 2025-07-24

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
70 enrolled
NCT04083170 2025-01-01

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Fred Hutchinson Cancer Center

Phase 2 Terminated
1 enrolled 11 charts
NCT00741455 2020-11-23

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

Dartmouth-Hitchcock Medical Center

Phase NA Completed
18 enrolled 7 charts
NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

M.D. Anderson Cancer Center

Phase 2 Completed
176 enrolled 18 charts
NCT01163201 2017-12-02

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Masonic Cancer Center, University of Minnesota

Phase 1/2 Withdrawn
NCT02118311 2017-12-02

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
NCT02259348 2017-05-30

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

St. Jude Children's Research Hospital

Phase 2 Terminated
12 enrolled 12 charts
NCT00049504 2017-05-17

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
53 enrolled 10 charts
NCT01621477 2017-02-20

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

St. Jude Children's Research Hospital

Phase 2 Terminated
34 enrolled 12 charts
NCT00809276 2015-02-16

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
92 enrolled 5 charts